ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023
Biopsy-proven CKD etiology and outcomes: the Chronic Kidney Disease Japan Cohort (CKD-JAC) study.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Interstitial palladin expression is associated with increased risk of end-stage kidney disease and death in patients with biopsy-proven diabetic kidney disease.Clinical and experimental nephrology · 2026Article
- Assessing kidney fibrosis via multiparametric MRI in native kidney and allografts.Clinical kidney journal · 2026Article
- Review no. 1: designing clinical kidney research using real-world data: research questions, data sources, and analytical skills.Clinical and experimental nephrology · 2026Review
- Conventional machine learning-based prediction models did not outperform the International IgA Nephropathy Prediction Tool.Kidney research and clinical practice · 2025Article
- Association of diabetic retinopathy with kidney disease progression according to baseline kidney function and albuminuria status in individuals with type 2 diabetes.Clinical and experimental nephrology · 2025Article
- Kidney lesions and risk of cardiovascular events in biopsy-proven diabetic kidney disease with type 2 diabetes.Clinical and experimental nephrology · 2025Article
- Emerging New Era of Artificial Intelligence and Digital Medicine-directed Management of Chronic Kidney Disease.JMA journal · 2025Article
- Long-term Outcomes of Lupus Nephritis in Comparison to Other CKD Etiologies.Kidney international reports · 2025Article
- Primary glomerular diseases and long-term adverse health outcomes: A nationwide cohort study.Journal of internal medicine · 2025Article
- International Nephrology Masterclass in Chronic Kidney Disease: Rationale, Summary, and Future Perspectives.Life (Basel, Switzerland) · 2024Review
- Prognostic factors affecting long-term outcomes in patients with concurrent IgA nephropathy and membranous nephropathy.Heliyon · 2024Article
- Conceptualizing Treatment Strategies for Diabetic Kidney Disease: the Importance of Early Diagnosis and Treatment.Juntendo Iji zasshi = Juntendo medical journal · 2024Article
- Cystacin C-based eGFR and Creatinine Clearance-based eGFR in Patients with Severe Motor and Intellectual Disabilities.JMA journal · 2023Article
- Detection of N‑glycoprotein associated with IgA nephropathy in urine as a potential diagnostic biomarker using glycosylated proteomic analysis.Experimental and therapeutic medicine · 2023Article
- Kidney Health and Care: Current Status, Challenges, and Developments.Journal of personalized medicine · 2023Article
- A low rate of end-stage kidney disease in membranous nephropathy: A single centre study over 2 decades.PloS one · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Kidney Disease: Improving Global Outcomes guidelines advocate the cause-glomerular filtration rate (GFR)-albuminuria (CGA) classification for predicting outcomes. However, there is a dearth of data supporting the use of the cause of chronic kidney disease. This study aimed to address how to incorporate a prior biopsy-proven diagnosis in outcome prediction.
methodsWe examined the association of biopsy-proven kidney disease diagnoses with kidney failure with replacement therapy (KFRT) and all-cause death before KFRT in patients with various biopsy-proven diagnoses (n = 778, analysis A) and patients with diabetes mellitus labeled with biopsy-proven diabetic nephropathy (DN), other biopsy-proven diseases and no biopsy (n = 1117, analysis B).
resultsIn analysis A, adding biopsy-proven diagnoses to the GFR-albuminuria (GA) classification improved the prediction of 8-year incidence of KFRT and all-cause death significantly regarding integrated discrimination improvement and net reclassification index. Fine-Gray (FG) models with KFRT as a competing event showed significantly higher subdistribution hazard ratios (SHRs) for all-cause death in nephrosclerosis {4.12 [95% confidence interval (CI) 1.11-15.2)], focal segmental glomerulosclerosis [3.77 (95% CI 1.09-13.1)]} and membranous nephropathy (MN) [2.91 (95% CI 1.02-8.30)] than in immunoglobulin A nephropathy (IgAN), while the Cox model failed to show significant associations. Crescentic glomerulonephritis had the highest risk of all-cause death [SHR 5.90 (95% CI 2.05-17.0)]. MN had a significantly lower risk of KFRT than IgAN [SHR 0.45 (95% CI 0.24-0.84)]. In analysis B, other biopsy-proven diseases had a lower risk of KFRT than biopsy-proven DN in the FG model, with death as a competing event [SHR 0.62 (95% CI 0.39-0.97)].
conclusionsThe CGA classification is of greater value in predicting outcomes than the GA classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.